Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model by Nestvold, Janne M. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=koni20
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: http://www.tandfonline.com/loi/koni20
Oncolytic peptide LTX-315 induces an immune-
mediated abscopal effect in a rat sarcoma model
Janne Nestvold, Meng-Yu Wang, Ketil A. Camilio, Severin Zinöcker, Torunn
Elisabeth Tjelle, Alf Lindberg, Bengt Erik Haug, Gunnar Kvalheim, Baldur
Sveinbjørnsson & Øystein Rekdal
To cite this article: Janne Nestvold, Meng-Yu Wang, Ketil A. Camilio, Severin Zinöcker, Torunn
Elisabeth Tjelle, Alf Lindberg, Bengt Erik Haug, Gunnar Kvalheim, Baldur Sveinbjørnsson & Øystein
Rekdal (2017) Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat
sarcoma model, OncoImmunology, 6:8, e1338236, DOI: 10.1080/2162402X.2017.1338236
To link to this article:  https://doi.org/10.1080/2162402X.2017.1338236
© 2017 The Author(s). Published with
license by Taylor & Francis Group, LLC©
Janne Nestvold, Meng-Yu Wang, Ketil A.
Camilio, Severin Zinöocker, Torunn Elisabeth
Tjelle, Alf Lindberg, Bengt Erik Haug, Gunnar
Kvalheim, Baldur Sveinbjørnsson, and
Øystein Rekdal
Accepted author version posted online: 16
Jun 2017.
Published online: 17 Aug 2017.
Submit your article to this journal 
Article views: 421
View related articles 
View Crossmark data
ORIGINAL RESEARCH
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat
sarcoma model
Janne Nestvolda,*, Meng-Yu Wangb,c,*, Ketil A. Camiliob,d, Severin Zin€ockere, Torunn Elisabeth Tjelle f, Alf Lindbergd,
Bengt Erik Haug g, Gunnar Kvalheimc, Baldur Sveinbjørnsson d,h, and Øystein Rekdal d,h
aDepartment of Transplantation Medicine, Institute for Surgical Research, Oslo University Hospital, NO-0732 Oslo, Norway; bDepartment of Tumor
Biology, Institute for Cancer Research, Oslo University Hospital, NO-0379 Oslo, Norway; cDepartment of Cellular Therapy, Oslo University Hospital,
NO-0379 Oslo, Norway; dLytix Biopharma, Gaustadalleen 21, NO-0349 Oslo, Norway; eDepartment of Anatomy, Institute of Basic Medical Sciences,
Faculty of Medicine, University of Oslo, N-0317, Oslo, Norway; fDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine,
University of Oslo, N-0317, Oslo, Norway; gDepartment of Chemistry and Centre for Pharmacy, University of Bergen, Allegaten 41, NO-5007 Bergen,
Norway; hDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, NO-9037 Tromsø, Norway
ARTICLE HISTORY
Received 18 April 2017
Revised 26 May 2017
Accepted 27 May 2017
ABSTRACT
LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we
demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic
immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted
in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant
infiltration of CD8C T cells was observed in both treated and non-treated lesions, as shown by
immunohistochemical and flow cytometric analysis. LTX-315 rapidly killed the cells in vitro with a lytic
mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP)
molecules such as HMGB1, ATP and Cytochrome c. Together, our data demonstrate that LTX-315







Host defense peptides, commonly also denoted as cationic
antimicrobial peptides (CAPs), are found in virtually all
species of life and are a part of the innate immune system.1
CAPs vary in amino acid sequence and chemical structure,
but in general they are short (< 40aa), are abundant in cat-
ionic residues and acquire amphipathic properties. Their
amphipathic nature and cationic charge are both important
modalities for their ability to interact with, and destabilize
anionic lipid membranes in cancer cells.2 Although their
most studied function is the defense against microorganism
such as bacteria, CAPs also have been shown to exert activi-
ties against cancer cells.3,4
We have described previously the development of a 9-
mer oncolytic peptide LTX-315.5,6 The peptide is highly
effective against both drug-resistant and drug-sensitive can-
cer cells, and displays a lower activity toward normal non-
malignant cells.7 The mechanism of cell death includes a
membranolytic effect on the cellular plasma membrane, as
well as cytosolic organelles such as mitochondria, Golgi and
lysosomes.8,9 The membranolytic mode of action leads to a
subsequent release of danger-associated molecular pattern
molecules (DAMPs) and tumor antigens that recruit and
activate dendritic cells with a subsequent T-cell activation
and specific immune response.9 Intratumoral (i.t.) treatment
with LTX-315 results in growth inhibition, complete regres-
sion and long-lasting tumor-specific immune responses in a
variety of different experimental animal models.10,11
In the present study, we investigated the oncolytic effect of
LTX-315 in a rat fibrosarcoma model, based on a spontane-
ously transformed rat mesenchymal stem cell line (rTMSC).12
The transformed cell line maintained features of mesenchymal
stem cells, and at the same time possessed properties and char-
acteristics of cancer stem cells (CSCs). Side population (SP) iso-
lation and tumorsphere cultivation of the transformed cells
confirmed the presence of putative CSCs among the rTMSCs.
In vivo studies demonstrated functional heterogeneity among
the transformed rMSCs, and indicated the SP subset as respon-
sible for tumor development. Tumor-initiating cells/cancer
stem cells are associated with an increased resistance to conven-
tional chemotherapy and radiation,13 making the tumor cell
subset a suitable target for LTX-315 treatment.
Here, we report that i.t. injections with LTX-315 resulted in
a complete regression of established fibrosarcomas. The treat-
ment resulted in a T-cell-dependent and tumor-specific
immune response associated with the infiltration of CD8C T
cells into the tumor bed. Furthermore, T-cell infiltration and
regression was also observed in non-treated distal lesions,
hence indicating a strong abscopal effect of the treatment with
LTX-315.
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Results
LTX-315 has a rapid mode of action compared with
conventional chemotherapeutics
The cytotoxic effect of LTX-315 was compared with commonly
used chemotherapeutic drugs (dacarbazine, temozolomide and
cisplatin), using the MTT assay. LTX-315 exhibited a more rapid
cytotoxic effect against the murine rTMSC cell line compared
with the chemotherapeutic drugs, as shown by an IC50 value of
7 mM 2 h post-treatment, compared with >100 mM for all the
chemotherapeutics. A significant anticancer effect for the chemo-
therapeutic drugs was first observed after 24 h (Fig. 1).
Rat TMSC cells treated in vitro with LTX-315
release DAMPs
To study whether LTX-315 was able to induce the release of
DAMPs, which is one of the requirements for immunogenic cell
death, the release of ATP, cytochrome c and HMGB1 from LTX-
315-treated rTMSC cells was measured. rTMSC cells treated with
17 mM LTX-315 exhibited a gradual release of all DAMPs, with
an increasing concentration of ATP, cytochrome c and HMGB1
as time progressed. Untreated control cells showed little or no
release of ATP, HMGB1 and Cytochrome c (Fig. 2A-C).
Intratumoral injections with LTX-315 induce a complete
regression and systemic immune responses against rTMSCs
To investigate the effect of LTX-315 in the rTMSC model, we
injected LTX-315 into established subcutaneous lesions in PVG
Figure 1. In vitro cytotoxicity of LTX-315 compared with conventional chemothera-
peutics. Cytotoxicity data demonstrating IC50 values of LTX-315 (red line) and 3 dif-
ferent chemotherapeutic drugs, dacarbazine (orange line), temozolomide (green
line) and cisplatin (blue line) after designated time points (2, 4, 8, 24 and 48 h). For
each time point, the mean of 3 experiments are presented.
Figure 2. LTX-315 treatment leads to extracellular release of DAMPs in vitro. Rat TMSCs were treated in vitro with 17 mM of LTX-315 (IC50) for selected time points (5, 10, 30 and
60 min), and analyzed for the release of ATP, Cytochrome c and HMGB1. (A) LTX-315-treated cells showed a rapid release of ATP into the supernatant with a peak around 10 min
before a subsequent descent after 30 min. (B) Similarly, LTX-315-treated cells displayed an increase in cytochrome c release related to incubation time with a significant amount
in the supernatant after 30 and 60 min. (C) Rat TMSCs treated with LTX-315 showed a translocation of the HMGB1 protein from the lysate (L) to the supernatant (S) using
Western blot. Control cells showed no translocation after 60 min. All experiments were performed in triplicate, and quantitative data are presented as a mean§ SD.
e1338236-2 J. NESTVOLD ET AL.
rats (Fig. 3A). The efficacy of LTX-315 treatment was monitored
by bioluminescence imaging (BLI) of luciferase-transfected
rTMSCs, including the measurement of tumor size. In 6 out of 6
rats receiving intratumoral treatment with LTX-315, tumor tissue
necrosis was observed and complete regression (CR) was obtained
20 d after tumor inoculation. In control rats receiving saline injec-
tions, luciferase activities reflecting tumor growth gradually
increased with time until termination at day 9 (Fig. 3B and C).
We then examined whether persistent protective immune
responses could be achieved after LTX-315 treatment by rechal-
lenging the rats s.c. with rTMSCs in the opposite flank 6 weeks
posttreatment. In 6 out of 6 animals previously cured by LTX-
315, tumor growth was inhibited and the rats were tumor-free
on day 6, whereas the control rats developed tumors and were
killed on day 6 (Fig. 3D and E). Similar results were obtained
with rTMCS cells that were not transfected with dual reporter
gene luciferase and GFP (data not shown).
To assess whether LTX-315 was able to elicit a systemic anti-
tumor response, rats were given a third challenge i.p. 13 weeks
post-initial treatment. After tumor cell implantation, spread
bioluminescence activities were observed in the peritoneal cav-
ity. The luciferase activities gradually decreased until day 8, as
the tumor cells were eradicated in 6 out of 6 animals previously
treated with LTX-315. In contrast, progressive tumor growth in
the peritoneal cavities was observed in control rats, terminated
on day 8 (Fig. 3D and E). The data demonstrate that LTX-315
treatment induced a complete regression and protective sys-
temic immune responses against rTMSCs.
LTX-315 treatment induces long-term persistence
of protective immune responses
To evaluate whether durable immunologic memory responses
were developed in the treated rats, the rats were rechallenged
Figure 3. Intratumoral administration of LTX-315 inhibits rTMSC growth (A). The time schedule of LTX-315 injections and tumor rechallenge experiments. Tumors were
established by an s.c. inoculation of 5¢105 rTMSCs in the right flank of syngeneic PVG rats. On days 3, 5, 6 and 7 after tumor inoculation, experimental rats (n D 6) were
given an i.t. injection of 1 mg LTX-315. Age-matched control rats (n D 6) received injections of saline in parallel. Antitumor responses were assessed by bioluminescence
imaging (BLI) of luciferase-expressing tumor cells, images were acquired at the indicated days post-tumor inoculation. (B) Representative whole-body images of rats dur-
ing treatment with LTX-315 or saline vehicle control. Total luciferase activity is summed up and depicted in figure (C), showing tumor progression and response to LTX-
315 treatment. The bold line refers to treated rats, while the dashed line represents the pattern for saline vehicle. A mean § SD in the treatment group is compared with
the controls. The 6 treated rats designated as tumor-free were rechallenged s.c. with 2¢104 rTMSCs in the opposite flank in week 6, while other na€ıve rats were included
as controls (n D 6). (D) Representative images of previously treated rats and controls after the second s.c. challenge with tumor cells and (E) graph charting the tumor
growth. Values are expressed as a mean § SD of hexaplicates in treated and control rats. The experimental animals survived the second challenge without signs of tumor
growth, and were exposed to a third challenge of tumor cells in week 13 administered by an i.p. inoculation of 2¢105 rTMSCs. A control group was included (n D 6). (F)
Representative images of animals initially treated with LTX-315 after i.p. challenge, including control rats. (G) Graph charting intraperitoneal tumor progression in treated
and control rats. The data are the mean § SD of hexaplicates.
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both s.c. and i.p. with rTMSCs 60 weeks after treatment (Fig. 4A).
In 8 out of 8 rats initially cured by LTX-315, rapid tumor regres-
sion occurred in the subcutaneous site (Fig. 4B and C) and in the
peritoneal cavity (Fig. 4D and E), whereas the control rats devel-
oped subcutaneous and peritoneal tumors and were killed on day
18. The inhibition of tumor growth in long-term survivors sug-
gests that intratumoral LTX-315 treatment induced long-term
protective systemic immune responses.
Local LTX-315 treatment causes complete regression
of non-treated tumors at distant sites
Based on the results of the rTMSC rechallenge experiments
and our recent findings that LTX-315 could induce a strong
systemic protective immune response in the B16 melanoma
model,10 we aimed to investigate whether the intratumoral
administration of LTX-315 could induce effects against non-
targeted lesions. For the evaluation of this hypothesis, we
established tumors at 3 different sites to mimic tumor cell
dissemination and the formation of metastasis (Fig. 5A). A
tumor in one flank, defined as the primary site, received i.t.
injections of LTX-315. The second lesion in the opposite
flank and a third lesion within the peritoneal cavity were left
untreated. In 12 out of 12 rats, i.t. injections of LTX-315
eradicated the primary lesion within 11 d after tumor cell
inoculation (Fig. 5B and C). Complete regression of the sec-
ondary lesion and the third peritoneal tumor were observed
on day 19 (Fig. 5D and E) and day 9 (Fig. 5F and G), respec-
tively. Control rats developed tumors and were terminated
on day 9 (primary lesion), day 19 (secondary lesion) and day
14 (peritoneal tumor). We observed that LTX-315 treatment
eradicated both the treated lesion and the disseminated
tumors, thereby indicating a strong and immediate systemic
effect of LTX-315 therapy.
Adoptive transfer of splenocytes from donors cured by
LTX-315 protects against rTMSC tumor growth
We further examined whether the protective immune
response induced by LTX-315 could be transferred to na€ıve
Figure 4. Initial LTX-315 treatment elicits long-term tumor protection. (A) Time schedule of experiment to study long-term effects of LTX-315 therapy. Rats were s.c. inoc-
ulated with 1¢105 rTMSCs in the upper flank. At day 6, rats in the treatment group (n D 8) received an i.t. injection of 1 mg LTX-315 daily for 7 consecutive days. Rats in
the control group (n D 6) remained untreated, and were killed after gross tumor development. The LTX-315 treated rats were considered cured and housed for 60 weeks
before s.c. and i.p. rechallenge with 2 £ 104 rTMSCs. Other control rats (n D 6 for each tumor site) were included. Representative luminescence images after (B) s.c. and
(D) i.p. tumor rechallenge, total photon flux is summarized (mean § SD) and depicted (C, E).
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recipients by adoptive transfer of splenocytes from cured
rats (Fig. 6A). The lymphoid compartment of recipient ani-
mals was depleted by total body irradiation (TBI) before
adoptive transfer, while the transfer of splenic lymphocytes
from cured rats inhibited subcutaneous tumor growth in 15
out of 15 recipients (Fig. 6B). In contrast, 5 out of 5 rats
receiving splenocytes from na€ıve animals were not protected
and were terminated due to gross tumor size. Thus, protec-
tive immune responses against rTMSCs can be adoptively
transferred from previously treated rats to na€ıve recipients.
To determine whether the growth-inhibitory response in
recipient rats receiving splenocytes from cured donors could be
attributed to T cells, a group of rats were given T-cell-depleted
(TCD) spleen cells. The transfer of TCD splenocytes did not
protect against tumor development in 6 out of 6 rats, and there
were only minute differences in survival between recipients
receiving TCD spleen cells (12. 5 § 0.5 days) and those trans-
ferred with splenocytes from na€ıve rats (15.8 § 0.8 days)
(Fig. 6C). The lack of tumor inhibition in the recipients of TCD
splenocytes from cured donors suggests an essential protective
role for T cells in LTX-315 mediated-antitumor immune
responses.
The protective immune response induced by LTX-315 is
tumor-specific
After the adoptive transfer of splenocytes from animals cured
by LTX-315, the specificity of the antitumor immune responses
was investigated by challenging the recipient rats with rTMSCs
in one flank and a different syngeneic tumor cell line, Roser’s
T-cell leukemia (RL) cells, in the contralateral flank (Fig. 7A).
In 3 out of 3 rats, we observed a rapid and complete regression
of the rTMSC tumor, while the RL tumor in the opposite flank
developed and grew large (Fig. 7B). A flow cytometric analysis
of the harvested RL tumors confirmed a dominant leukemic
CD3CCD4C cell population (Fig. 7C), distinct from tumor-
infiltrating lymphocytes (TILs) in rTMSC tumors (Fig. 8B).
The growth inhibition of the rTMSC tumor, coincident with
the tumor progression of the irrelevant RL tumor, indicates
that intratumoral LTX-315 treatment leads to the induction of
tumor-specific immune responses.
To further evaluate the specificity of the immune response,
we measured the cytotoxic activity of isolated T cells from pre-
viously LTX-315-treated rats compared with na€ıve controls
against rTMSCs and the irrelevant RL cells using a 4 h 51Cr
Figure 5. The abscopal effect of LTX-315 in a 3-tumor model. (A) Tumor cells (2¢105 rTMSCs) were inoculated on day 2 s.c. in the right flank (primary treated
lesion), day 0 (1¢104 rTMSCs) s.c. in the contralateral flank (secondary non-treated lesion) and (1¢104 rTMSCs) i.p. (tertiary non-treated lesion) into PVG rats
(n D 12). The primary lesion was treated with 1 mg of LTX-315 i.t. daily for 7 d. Control rats (n D 3) for each tumor site were included. Representative whole-
body bioluminescence images of LTX-315 treated and untreated rats; (B) primary lesion, (D) secondary lesion and (F) peritoneal tumor are presented. The
mean § SD of tumor burden is plotted (treated; bold line, untreated; dashed line) for the primary (C), the secondary (E) and the third (G) tumor. Results are
presented as a mean § SD.
ONCOIMMUNOLOGY e1338236-5
release assay (Fig. 7D and E). Without in vitro stimulation, T
cells obtained from the spleens of cured animals were able to
recognize and lyse rTMSC targets. Significant rTMSC-specific
cytolysis of T cells were noted compared with T cells from na€ıve
animals (effector: target ratio of 100:1, cured rats; 9.73 § 1.70,
na€ıve rats, 1.07 § 0.85, P < 0.0001, 50:1, cured rats; 5.16 §
1.18, na€ıve rats; 0.00 § 0.0, P < 0.0001), whereas negligible
cytotoxic activity against RL targets was observed. When puri-
fied T cells from na€ıve spleens were used as effector cells, no or
negligible cytolytic activity against rTMSCs or RL cells was
detected. Taken together, both the in vivo and the in vitro data
confirm that T cells were responsible for the persistent tumor-
specific immune responses in recipients transferred with sple-
nocytes from LTX-315-cured donors.
LTX-315 treatment leads to increased tumor infiltration
of CD8C T cells
To investigate the cellular mechanisms underlying LTX-315-
mediated regression and long-term protective immune
responses, we analyzed the cellular composition of treated
tumors by flow cytometry and immunohistochemistry. During
the week after the last treatment, tumors were resected at differ-
ent time points, and thereafter TILs were phenotyped in both
LTX-315-treated and untreated animals (Fig. 8A). The gating
strategy for T (CD3CNKR¡P1A¡) cells, CD4C and CD8C T
cells, CD4CFoxP3CT cells and NK (NKR-P1ACCD3¡) cells is
shown (Fig. 8B).
Tumor-infiltrating lymphocytes in response to growing
tumors were observed in untreated animals (Fig. 8C). A signifi-
cantly higher proportion of NK cells were also present in pro-
gressive untreated tumors versus treated regressive tumors
(untreated; 9.28% § 6.22, treated; 2.26 § 0.89, P < 0.5), which
may reflect an NK-mediated early immune response in pro-
gressive tumors. The spontaneous infiltration of lymphocytes
was insufficient to inhibit tumor growth, and tumor control
was dependent on adaptive immunity and the accumulation of
CD8C T cells in the tumor microenvironment. The percentage
of T cells was significantly increased after LTX-315 treatment
compared with untreated tumors (treated; 28.35 § 11.78,
untreated; 13.58 § 7.84, P < 0.5). Similarly, the percentage of
T cells within secondary tumor tissue increased 3-fold com-
pared with untreated rats (treated; 39.83 § 17.4, untreated;
11.83 § 10.25, P < 0.01). Within the CD3CT cell population,
CD8Ccells accounted for the major fraction in primary and sec-
ondary tumors of treated rats vs. untreated controls (primary
tumor of treated rats; 62.77 § 13.3, untreated rats; 37.33 §
3.48, P < 0.01, secondary tumor of treated rats; 45.8 § 5.4,
untreated rats; 34.67 § 3.36, P < 0.1). There was no significant
difference in the relative percentage of infiltrating CD4C T cells
and CD4CFoxp3C regulatory T cells (Tregs) between the pri-
mary tumors of treated and untreated animals. In the second-
ary tumors of untreated animals, we found a higher percentage
of CD4CT cells compared with treated rats (treated; 38.0 § 4.0,
untreated; 54.7 § 9.0, P < 0.01) and Tregs (treated; 2.21 §
1.43, untreated; 5.17 § 2.50, P < 0.5). In line with other
Figure 6. T cells originated from adoptively transferred splenocytes of donors cured by LTX-315 and inhibit the development of rTMSCs in na€ıve recipients. (A) Recipient
rats were conditioned with total body irradiation (TBI) of 600 cGy one day before adoptive spleen cell transfer. Surviving rats were rechallenged twice after the initial
LTX-315 treatment was used as a splenocyte donor. A group of rats (n D 15) received isolated spleen cells (30¢106) from cured rats. Another group of rats (n D 6) were
given T-cell depleted (TCD) splenocytes (18¢106) from cured donors, whereas spleen cells (30¢106) from na€ıve rats were transferred to rats in the control group (n D 5).
One day after splenocyte transfer, animals were s.c. inoculated with 1¢104 rTMSCs. The measurement of tumor development was tracked by bioluminescence imaging. (B)
Representative images of recipient rats receiving spleen cells from cured donors (LTX-315), or from na€ıve donors (control) at designated days after tumor challenge. (C)
Survival curve comparing tumor-free survival in animals receiving splenocytes from cured donors (solid line), TCD fraction of splenocytes (dashed line) or splenocytes
from na€ıve donors (dotted line).
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reports, the higher percentage of Tregs in secondary lesions in
untreated vs. treated rats is associated with immune suppres-
sion and poor prognosis in many types of solid tumors.14
Akin to untreated rats, a FACS analysis of LTX-315-treated
rats revealed significantly elevated levels of CD3C and CD8C
tumor-infiltrating T cells, the major immune effector cell popu-
lation15 that correlated with tumor regression. Immunohisto-
chemical analysis was consistent with the flow cytometry data
demonstrating an increased infiltration of CD3C and CD8C
cells observed in primary and secondary tumor tissues from
LTX-315-treated rats (Fig. 8D).
Discussion
The identification, isolation and characterization of CSCs in
various types of cancers expedite the development of targeted
therapeutic strategies aiming to eradicate CSCs to prevent
relapse and metastasis.16,17 The new class of local immunother-
apy for cancer, oncolytic peptides, gain more selectivity against
cancer cells vs. normal cells due to the higher abundance of
anionic membrane components of cancer cells compared with
normal cells.18 Moreover, oncolytic peptides are equally effec-
tive against cancer cells displaying dormancy and drug resis-
tance. We have previously reported the design of an oncolytic
peptide LTX-315, which induces membrane permeabilization
and interaction with intracellular targets such as mitochondria,
ultimately resulting in tumor cell lysis.5,6,8,9,19 Intratumoral
treatment with LTX-315 induces complete tumor regression
and tumor-specific immune protection in a variety of different
experimental animal models.10,11 In the present study, the
oncolytic effects of LTX-315 were investigated in rTMSC
tumors composed of heterogeneous population of cells with
various degrees of differentiation.12 Intratumoral treatment
with LTX-315 caused a complete regression (CR) in all treated
animals, and no adverse effects on behavior and physiology
were observed. The generation of long-term and systemic
immune responses was verified by tumor rejection and protec-
tion from rTMSCs after rechallenging rats up to 14 months
after the initial LTX-315 treatment.
The abscopal effect, a rare event usually observed during
localized radiation therapy or combination therapy,20-22 was
further evaluated in a 3-tumor model. Upon treatment of a
Figure 7. Anti-tumor immune responses induced by LTX-315 are tumor-specific. (A) After the adoptive transfer of splenocytes from cured rats, surviving rats (nD 3) were
s.c. rechallenged with 1¢105 rTMSCs in the right flank and subsequently s.c. inoculated with a different syngeneic tumor cell line, Roser’s T-cell leukemia (RL, 1¢105 cells) in
the contralateral flank. Tumor growth was monitored by measurements of tumor diameter using calipers. (B) A schematic presentation of growth curves (mean § SD),
demonstrating specificity and the inhibition of rTMSC growth. On day 30, when the left-flank RL tumors reached 100 mm2 in size, the tumors were resected and processed
for flow cytometric characterization. (C) Representative dot plot showing the morphological characteristics of single-cell suspensions from RL tumors. Gating on the lym-
phocyte population and staining with anti-CD3 and anti-NKR-P1A revealed the frequency of T (CD3C NKR-P1A¡) cells. Phenotypic analysis of the T cell fraction is shown
in the histograms, indicating the percentage of CD4C and CD8C T cells. A standard 4-h 51 Cr release assay was performed to quantitatively measure the cytolytic effect of
tumor-specific T cells. T cells were enriched from the spleens of long-term survivors (week 60) after the adaptive transfer of tumor-reactive splenocytes. One na€ıve rat
was included as a control. Without in vitro activation, isolated T cells were tested in cytotoxicity assays at a varying effector: target (E: T) ratios against (D) rTMSCs and (E)
RL target cells. The results are reported as a mean of cpm § SD of technical triplicates. P < 0.0001, with Student’s t test.
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single tumor with LTX-315, rapid tumor regression was
observed not only in the treated lesion, but also in the
untreated, distant lesions. The abscopal response, associated
with a systemic anti-tumor response to local therapy, was
clearly T-cell-mediated. Whereas rTMSC growth could be
impeded by adoptively transferred splenocytes from LTX-315-
cured animals, TCD splenocytes did not affect tumor growth.
The tumor-specificity of the splenic T cells was demonstrated
by the in vivo and in vitro inhibition of rTMSCs, concurrently
with the lack of tumor suppression and cytotoxicity vs. an irrel-
evant, syngeneic (RL) tumor cell line.
LTX-315 exerted rapid kill kinetics compared with conven-
tional chemotherapeutic drugs against the rTMSC cell line in
vitro, hence demonstrating the lytic mode of action of the pep-
tide. The cytolytic activity and immunomodulatory properties
of LTX-315 have recently been described (8, 9, 19, 23, 24),
involving the perturbation of both the cell membrane and the
mitochondria accompanied by the release of DAMPS such as
ATP, Cytochrome c and HMGB1, thus signaling tissue damage
to the surrounding tumor microenvironment. The LTX-315-
mediated tumor cell lysis and subsequent release of membrane-
bound and intracellular components might augment the level
of tumor-associated antigens and neoantigens available for T-
cell priming by dendritic cells. Of note, aberrant mitochondrial
RNA transcripts may contribute to changes associated with the
phenotype of a transformed cell, and may therefore serve as a
source of tumor antigen recognized by T cells.25 This process of
immunogenic cell death (ICD) may turn the LTX-315-treated
tumors into in situ vaccines eliciting tumor-specific T cells.26,27
The impact of the host immune cells in the tumor microen-
vironment has emerged as a critical determinant of tumor
depression or progression and the response to therapy.28,29 The
conventional classification of solid tumors (TNM) summarizes
data on tumor (T) nodes (N) and metastatic sites (M), and
pays no attention to the effect of the immune responses follow-
ing therapy.30 The Immunoscore concept considers the interac-
tions between tumor cells and host immune cells, and
uses measurement of the type, number and location of
Figure 8. Infiltrating lymphocytes are recruited into the tumor after LTX-315 treatment. (A) Schedule of experiment to study cell infiltration and modification of cell com-
position in tumors after LTX-315 treatment. Rats were s.c. inoculated with 2¢105 rTMSCs in one flank day 2 and 2¢104 rTMSCs in the opposite flank on day 0. Rats (n D
8) with pre-established tumors were given i.t. injections of 1 mg LTX-315 daily for 3 subsequent days. Tumor-bearing rats in the control group (n D 6) received saline
injections in parallel. Single-cell suspensions were prepared from fresh tumor tissue at different time points during the week after LTX-315 treatment. (B) Representative
dot plots of the morphological characteristics (SSC vs. FSC) exhibited by progressing tumors and LTX-315-treated tumors. Schematic illustration of gating: Tumor-infiltrat-
ing lymphocytes determined by forward and side scatter properties, stained with relevant antibodies for flow cytometric analysis to identify NK (NKR-P1ACCD3¡) cell and
T (CD3CNKR-P1A¡) cell populations, including CD4C and CD8C T cell subsets. The percentage of Tregs was derived from the percentage of FoxP3C cells within the total
CD4C T cell population. (C) Bar graphs showing the percentage of TIL subsets in primary treated lesion (light gray bars), secondary lesion (dark gray bars) of treated rats
compared with lesions from the control group (black bars). Graphs show the mean § SD. P < 0.5, P < 0.1 with Student’s t test. (D) Representative images of primary
and secondary tumors from treated rats vs. untreated controls stained for CD3 or CD8 (brown) and counterstained with DAPI (blue).
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tumor-infiltrating immune cells.31 Accumulating evidence indi-
cates that the density and ratio of tumor-infiltrating T cells
appear to be prognostic factors for clinical outcomes.32
Immunohistochemistry analyses combined with flow cytome-
try were performed to examine the phenotype of TILs in LTX-
315-treated and untreated tumor sites. Tumors injected with
vehicle exhibited a viable tissue with limited necrosis and a low
frequency of TILs. The intratumoral injection of LTX-315
induced extensive tumor necrosis and promoted a substantial
infiltration of CD8CT cells into the tumor environment and
parenchyma. The abscopal response was reflected in the increase
of cytotoxic T cells in distant, untreated lesions. The presence of
high densities of cytotoxic T cells correlated with tumor regres-
sion in the treated animals. Flow cytometry analysis verified the
significantly increased CD8C T-cell infiltration in both the pri-
mary and secondary tumor site, indicating that LTX-315 pro-
vokes and mediates the migration of tumor-specific T cells into
distant untreated sites, thereby intervening the process of metas-
tasis formation. In monitoring the anti-tumor effects of LTX-315,
we observed increased levels of TILs and alterations in the com-
position of the tumor T cell subsets. A novel approach in cancer
immunotherapy refers to tumors as hot or cold, depending on
how densely they are infiltrated in immune cells.33 In a cold
tumor, the recruitment of DCs and cytotoxic T cells is insufficient
to mount an effective anti-tumor response.34
Hot tumors with high frequencies of tumor-infiltrating cells
and consistent antigen exposure may escape an efficient immune
response by the upregulation of checkpoint inhibitory ligands.
Antibody-based checkpoint inhibitors (CPI) have emerged as a
promising approach in targeting negative T -cell regulators.35
Antibodies blocking the suppression of T-cell receptor signaling
through cytotoxic lymphocyte antigen 4 (CTLA-4), or interfering
with T-cell exhaustion via programmed cell death 1 receptors
(PD-1), have the potential to reinvigorate an antitumor immune
response. Cold tumors are resistant to checkpoint inhibitors
alone, leaving a large fraction of patients unresponsive to immune
checkpoint therapy. The therapeutic benefit is achieved in hot
tumors with pre-existing tumor-infiltrating CD8C T cells.36
The present study in the rat fibrosarcoma model indicates that
LTX-315 therapy-induced ICD can convert cold (low Immuno-
score) tumors, including distant, untreated tumors, to hot (high
Immunoscore) tumors. Indeed, the application of CTLA-4, in
combination with LTX-315, demonstrated a synergistic effect in a
murine model.11 Therefore, it is likely that LTX-315 may syner-
gize with checkpoint inhibitors and other treatment combina-
tions to help mount a persistent anti-tumor immune response.
To the establishment of platforms for combination therapies,
LTX-315 provides a treatment regimen optimized for both cyto-
toxic and immune activating effects. LTX-315 is currently being
tested in combination with anti-CTLA-4 in anti-PD-1 refractory
patients in melanoma patients, and with anti-PD1 in breast can-
cer patients.
Material and methods
Cell lines and reagents
Following the long-term culturing of bone marrow-derived rat
mesenchymal cells, a transformed mesenchymal cell (rTMSC)
line with maintained stemness properties was developed. The
cell line formed soft-tissue fibrosarcomas in immunocompro-
mised mice and syngeneic immunocompetent rats.12
Roser’s leukemia is a transplantable radiation-induced acute
T-cell leukemia induced in PVG rats.37
LTX-315 (K-K-W-W-K-K-W-Dip-K-NH2) was purchased
from Bachem AG and prepared on request. Dip is the aromatic
non-coded amino acid b-diphenylalanine. Dacarbazine (D2390),
temozolomide (T2577) and cis-diammineplatinum(II) dichloride
(P4394) were all purchased from Sigma-Aldrich.
In vitro cytotoxicity
A colorimetric 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetra-
zodium bromide (MTT) viability assay38 was used to assess
the in vitro cytotoxicity of LTX-315, as well as a selection of
cytostatic drugs against the rTMSC cell line. Pre-cultured cells
were transferred to a 96-well plate in subconfluent concentra-
tions at a volume of 100 ml/well (culture media). Cells were
left overnight in a cell incubator under conditions of 37 C;
>95% humidity and 5% CO2. Wells were plated in triplicate.
LTX-315 and the different cytostatic drugs were dissolved in a
serum-free RPMI 1640 and diluted to a concentration range
of 7–100 mM and 10–100 mM, respectively. The cytostatic
drugs were originally dissolved in dimethyl sulfoxide (DMSO)
and later in a serum-free RPMI 1640, yielding a final DMSO
concentration ranging from 0.5% in the 100 mM solution to
0.05% in the 10 mM solution. Cells were washed once with
serum-free RPMI 1640 before incubation with the peptide sol-
utions or cytostatic drugs for 2, 4, 8, 24 and 48 h, respectively.
Cells in a serum-free media alone were used as a negative con-
trol, while cells treated with 1% Triton X-100 (Sigma-Aldrich)
in a serum-free media were positive controls. A 10 ml MTT
solution (5 mg MTT per ml phosphate buffered saline) was
added to each well, and the incubation was continued for an
additional 2 h. Seventy microliters of solution were removed
from each well, and 100 ml of 0.04 M HCl in isopropanol was
added before the plates were shaken in an orbital shaker for
1 h at room temperature to help facilitate formazan crystal
solubilization. The absorbance was measured at 590 nm on a
microtiter plate reader (Thermomax Molecular Devices). The
percentage of viability was calculated as the A590 nm of pep-
tide-treated cells relative to the negative control (100% living
cells), and expressed as a 50% inhibitory concentration (IC50).
Release of ATP
The supernatant of LTX-315-treated rTMSCs was analyzed
using an ENLITEN ATP luciferase assay system (Promega,
FF2000). Cells were seeded (1 £ 104/well) in a 96-well plate,
and treated with the IC50 concentration of LTX-315
(17 mM) for varying time points (5, 10, 30 and 60 min).
All experiments were performed in duplicate a total of
3 times. Negative controls were untreated rTMSCs exposed
to a serum-free medium alone. Samples were analyzed using
a Luminoscan RT luminometer according to the manufac-
turer’s protocol.
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Release of cytochrome c
Rat TMSCs were seeded (5 £ 103/well) in a 96-well plate, and
treated with 17 mM LTX-315 for different time points (5, 10,
30 and 60 min). Supernatants were collected and concentrated
as with the HMGB1 release experiments. Samples were ana-
lyzed using a Quantikine ELISA Rat/Mouse Cytochrome c Elisa
kit (R&D Systems, MCTC0) following the manufacturer’s
instructions, and samples were run in duplicate for a total of 3
experiments and expressed as ng/ml cytochrome c released.
Release of HMGB1
Rat TMSCs (2 £ 105/well) were seeded in a 6-well plate,
treated with 17 mM LTX-315 (IC50) and incubated at 37 C,
5% CO2 and >95% humidity for different time points
(5–60 min). Serum-free RPMI 1640 was used as a negative
control. Supernatants were collected after centrifugation at
1,400 g for 5 min and up-concentrated using Amicon Ultra-
0.5 Centrifugal Filter units with Ultracel-50 membrane
(Millipore). Cell lysates were washed with serum-free RPMI
1640 and collected in a Mastermix containing a 2x NuPAGE
LDS Sample buffer (Invitrogen), a 1x NuPAGE Sample Reduc-
ing Agent (Invitrogen) and 50% sterile H2O. Supernatants and
cell lysates were boiled in a reducing NuPAGE LDS sample
buffer, resolved on NuPAGE Novex 4–12% Bis–Tris Gels, and
electrotransferred onto a polyvinylidene difluoride (PVDF)
membrane (Millipore). Membranes were hybridized with
HMGB1 antibody (rabbit polyclonal to HMGB1-ChIP Grade;
Abcam, ab18256), followed by a horseradish peroxidase
(HRP)-conjugated secondary antibody (goat polyclonal
anti-rabbit IgG; Abcam, ab6721) and developed by Western
blot luminol reagent (Santa Cruz Biotechnology) according to
the manufacturer’s instructions.
Animal experiments
Rats of the inbred Piebald Virol Glaxo (PVG.RT7a, abbreviated
PVG) strain were used interchangeably with the PVG.RT7b
strain (in this study abbreviated as PVG). The strains are iden-
tical except for one irrelevant epitope of the leukocyte common
antigen (LCA/CD45) family. PVG rats were purchased from
Harlan (the Netherlands) and PVG, and7B rats were obtained
from in-house breeding at the Institute of Basic Medical Scien-
ces (IMB, University of Oslo, Norway). During the experi-
ments, male rats, weighing 240–270 g each, were kept in groups
of 2 to 3 animals per cage under climate-controlled conditions,
with 12 h light/dark cycles and an ambient temperature. The
rats were housed in an enriched individually ventilated cage
(IVC) system with free access to standard rodent chow and
water ad libitum. The animals were anesthetized during the
experimental procedures with either 2.5% Isoflurane gas
(Baxter Medical AB) or received s.c. injections (0.4 ml/kg) of
fentanyl/fluanisone (Hypnorm; VetaPharma Ltd.), which pro-
vided a sufficient degree of sedation and analgesia. The animals
were monitored daily and large-tumor-bearing rats were killed
with CO2. All procedures performed were conducted under
FOTS numbers 1957 and 5917, and approved by the Experi-
mental Animal Board under the Ministry of Agriculture of
Norway and in compliance with The European Convention for
the Protection of Vertebrate Animals used for Experimental
and other Scientific Purposes. The laboratory animal facilities
are subjected to a routine health-monitoring program, and
were screened for common pathogens according to a modifica-
tion of the Federation of European Laboratory Animal Science
Association’s recommendation.
Tumor treatment
Pre-cultured rTMSCs were harvested in a serum-free RPMI-
1640 and s.c. inoculated into the right flank of PVG rats.
Established tumors (25 mm2 mean tumor size) were i.t.
injected with LTX-315 (dissolved in sterile H2O with 0.9%
NaCl) or with vehicle (sterile H2O with 0.9% NaCl). Treat-
ment doses of LTX-315, 50ml at 20 mg/ml, were given using a
0.5 ml syringe (Myjector U-100; Terumo) needle 0.5 £
16 mm (Fine-Ject; Henke-Sass, Wolf GmbH). Tumor size was
measured 3 times a week using a caliper, and expressed as the
area of an ellipse [(maximum dimension/2) x (minimum
dimension/2)]. Animals were terminated when the tumor
exceeded 400 mm2.
Whole imaging technique
The rTMSCs were engineered with a retroviral vector (kindly
provided by Dr. Rainer L€ow, EUFETS AG, Germany) to
express firefly luciferase and EGFP. After transfection with
rTMSCs, the GFP-positive cells were collected by FACS sorting,
and were used for all in vivo experiments. Tumor growth was
monitored by bioluminescent imaging using the IVIS 200 Spec-
trum CT System (Caliper Life Sciences). Anesthetized rats were
i.p. injected with a 150mg kg¡1 body weight of D-luciferin
(Biosynth). After 10 min, the luminescence emitted from the
luciferase rTMSCs was scanned by designing an auto program,
whereas data was analyzed with the Living Image v4.4 software
(Caliper Life Science).
Preparation of single cell suspensions from solid tumors
Tumors were gently minced with a razor blade, and cut into
small pieces (4 mm2). Tumor tissue was incubated with Lib-
erase TM (Thermolysin Medium; Roche Diagnostics) at a
concentration of 0.18 W€unsch units/ml in 10 ml MEM
media (Sigma-Aldrich) at 37C for 60 min with gentle agita-
tion. The enzymatic digestion was terminated by the addi-
tion of 2 ml 4C FCS (Invitrogen). The cell suspension was
filtered through a 70 mM mesh (Cell Strainer; BD), washed
in PBS, and cells were then directly used for flow cytometric
staining.
Antibodies and FACS analysis
The mouse monoclonal antibodies against CD4 (OX38), CD5
(OX19), CD6 (OX52) and CD8 (OX38) were isolated from cul-
ture supernatants from hybridomas, and were kind gifts from
the MRC Cellular Immunology Unit, Oxford, UK. They were
conjugated at IMB according to standard protocols. Fluoro-
chrome-conjugated mAbs against CD3 (G4.18, 559975) and
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NKR-P1A (10/78, 555009) were obtained from BD Biosciences,
including PerCP Streptavidin (554064). For the Treg analysis,
cells were surface stained for CD3 and CD4, then permeabilized
and stained for FoxP3 using Anti-mouse/rat Foxp3 Staining Set
(eBioscience, 72–5775–40). A 4-color panel consisting of
reagents in FITC/ Al488, PE, PerCP Streptavidin and Al647
was applied and analyzed on a FACS Calibur (BD) equipped
with the CellQuest software (BD). Dot plot and histogram gates
were set using isotype control antibodies.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections were
deparaffinized in xylene and graded alcohols, hydrated and
washed in PBS. After antigen retrieval in a sodium citrate buffer
(pH 6) in a microwave oven, the endogenous peroxidase was
blocked by 0.3% H2O2 for 15 min. Sections were incubated
overnight at 4 C with primary antibody, rabbit polyclonal
anti-CD3 (clone A0452, Dako) or mouse monoclonal anti-CD8
(ab33786, Abcam). As a secondary antibody, the anti-rabbit-
horseradish peroxidase (HRP) SuperPicTure Polymer detection
kit (Invitrogen) or Envision system HRP-anti-mouse (Dako)
was used. A matched isotype control was used as a control for
nonspecific background staining.
Splenocyte isolation and adoptive transfer
The animals were killed, and spleens from treated and na€ıve rats
were harvested through abdominal incision. Splenocytes were
isolated by density gradient centrifugation with Lymphoprep
according to the manufacturer’s instruction (Axis-Shield PoC).
A fraction of splenocytes was T-cell depleted (TCD) using the
MACS cell separation system (Miltenyi Biotec). The splenocytes
were incubated with saturating concentrations of biotinylated
mAbs, anti-CD5 (OX19) and anti-CD6 (OX52). After anti-
body-staining, cells were selected using appropriated diluted
anti-biotin microbeads. Labeled cells were separated using the
magnetic cell separator QuadroMACS. Isolated T cells were col-
lected from the bound fraction, while TCD splenocytes were
obtained from the unbound fraction of the LS column.
One day before the adoptive transfer of splenocytes, the rats
were conditioned with a total body irradiation (TBI) of 600 cGy
from a 137Cs source (Gammacell 3000 Elan, MDS Nordion).
Isolated splenocytes were resuspended in PBS and adjusted to a
concentration of 30¢106 cells/ml or 18¢106 cells/ml (TCD). The
day after, rats were s.c. inoculated with tumor cells.
In vitro T cell cytotoxicity assay
Freshly isolated splenic CD3C T cells from long-term survivors
without further in vitro activation were assessed for cytolytic
activity against rTMSCs and RL cells in a 4-h 51Cr-release
assay. Target cells (10¢106 cells ml-1) were incubated with 3.7
MBq of Na251CrO4 ml-1 for 1 h at 37C. 51Cr-labeled target
cells (1¢105 cells ml-1) and serial dilutions of effector cells at
the indicated E:T ratios were plated in 100ml of a complete
RPMI 1640 in U-bottomed 96-well plates.51 Cr-release was
measured after incubation for 4 h at 37C. Supernatants were
harvested with a Titertek harvesting system (Skatron), and
counted in a gamma counter (Beckmann). The percentages
lysis was determined using the formula (experimental cpm -
spontaneous cpm) x 100/ (maximum cpm - spontaneous cpm).
Spontaneous cpm was measured by incubating targets in a
medium alone, and was <15% of total cpm.
Statistics
Data are expressed as a mean § SD. Survival was estimated
with the Kaplan–Meier and log-rank tests for survival distribu-
tion. Statistical differences between the 2 groups were analyzed
by a 2-tailed Student’s t test, and a P < 0.05 was considered to
be statistically significant. Statistical analyses were performed
using GraphPad Prism software (version 6, GraphPad).
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